The Latin America, Middle East and Africa Cervical Cancer Diagnostic Market should witness market growth of 7.6% CAGR during the forecast period (2023-2029).
Cervical cancer is the fourth most frequent cancer and the main cause of mortality for women. Large pharmaceutical corporations are actively researching the best remedies for the same. Many potential pharmaceuticals and biologics are currently undergoing clinical testing. During the forecast period, the market is expected to develop due to the introduction of technologically improved computer-guided cervical cancer screening tests designed to decrease false-negative test results and increase accuracy.
Infection with the human papillomavirus (HPV) is the primary risk factor for developing cervical cancer. The majority of infections occur as a result of sexual activity, and the majority of people recover completely without any complications after contracting the virus. More than one hundred different types of HPV have been identified. The types or strains of HPV that are most commonly associated with an increased risk of cervical cancer include HPV16 and HPV18.
A weaker immune system increases the likelihood of acquiring cervical cancer in a person. Immune suppression by corticosteroid drugs, organ donation, therapies for different types of cancer, or the human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS), can all lead to a weakened immune system. A person's immune system is less competent to combat early cancer when they have HIV Herpes. Cervical cancer is more likely to strike those with genital herpes.
According to data from the “National Hospital Registry of Cancer” (NHRC), 20% of patients with cervical and vaginal cancer and 51% of those with endometrial cancer had their condition classified as International Federation of Gynecology and Obstetrics (FIGO) stage I. Because of this, the government is making more efforts to raise awareness of these diseases and the available preventative measures. The region's rising cervical cancer incidence will spur demand for diagnostics for early diagnosis and treatment, which will fuel market expansion in LAMEA.
The Brazil market dominated the LAMEA Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $172.3 Million by 2029. The Argentina market is experiencing a CAGR of 8.1% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 7.3% during (2023-2029).
Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.
Cervical cancer is the fourth most frequent cancer and the main cause of mortality for women. Large pharmaceutical corporations are actively researching the best remedies for the same. Many potential pharmaceuticals and biologics are currently undergoing clinical testing. During the forecast period, the market is expected to develop due to the introduction of technologically improved computer-guided cervical cancer screening tests designed to decrease false-negative test results and increase accuracy.
Infection with the human papillomavirus (HPV) is the primary risk factor for developing cervical cancer. The majority of infections occur as a result of sexual activity, and the majority of people recover completely without any complications after contracting the virus. More than one hundred different types of HPV have been identified. The types or strains of HPV that are most commonly associated with an increased risk of cervical cancer include HPV16 and HPV18.
A weaker immune system increases the likelihood of acquiring cervical cancer in a person. Immune suppression by corticosteroid drugs, organ donation, therapies for different types of cancer, or the human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS), can all lead to a weakened immune system. A person's immune system is less competent to combat early cancer when they have HIV Herpes. Cervical cancer is more likely to strike those with genital herpes.
According to data from the “National Hospital Registry of Cancer” (NHRC), 20% of patients with cervical and vaginal cancer and 51% of those with endometrial cancer had their condition classified as International Federation of Gynecology and Obstetrics (FIGO) stage I. Because of this, the government is making more efforts to raise awareness of these diseases and the available preventative measures. The region's rising cervical cancer incidence will spur demand for diagnostics for early diagnosis and treatment, which will fuel market expansion in LAMEA.
The Brazil market dominated the LAMEA Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $172.3 Million by 2029. The Argentina market is experiencing a CAGR of 8.1% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 7.3% during (2023-2029).
Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.
Scope of the Study
By Type
- Pap Smear Tests
- Colposcopy Tests
- HPV Test
- Biopsy & ECC
- Others
By Age Group
- 20 to 40 years
- Above 40 years
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Becton, Dickinson and Company
- Carl Zeiss AG
- CooperSurgical, Inc. (The Cooper Companies, Inc.)
- DYSIS Medical, Inc.
- F.Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Qiagen N.V.
- Siemens Healthineers AG (Siemens AG)
- Thermo Fisher Scientific, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Cervical Cancer Diagnostic Market by Type
Chapter 5. LAMEA Cervical Cancer Diagnostic Market by Age Group
Chapter 6. LAMEA Cervical Cancer Diagnostic Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Becton, Dickinson and Company
- Carl Zeiss AG
- CooperSurgical, Inc. (The Cooper Companies, Inc.)
- DYSIS Medical, Inc.
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Qiagen N.V.
- Siemens Healthineers AG (Siemens AG)
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
